Yale Cancer Center | Strategic Alliance Partners

home / sap-partner / cancer-centers / yale-cancer

Yale Cancer Center (YCC) is one of only 56 National Cancer Institute-designated comprehensive cancer centers in the nation and the only such center in Connecticut. Cancer treatment for patients is available at Smilow Cancer Hospital through 13 multidisciplinary teams and at 15 Smilow Cancer Hospital Care Centers in Connecticut and Rhode Island. Comprehensive cancer centers play a vital role in the advancement of the NCI’s goal of reducing morbidity and mortality from cancer through scientific research, cancer prevention, and innovative cancer treatment.

Latest from Yale Cancer Center

Dr. Lynch Accepts His 'Giants of Cancer Care' Award

By Thomas J. Lynch, Jr., MD

July 29th 2013

Thomas J. Lynch, Jr., MD, from the Yale Cancer Center, pioneered the use of molecular testing for EGFR mutations in lung cancer. In July 2013, he was honored by OncLive as one of the "Giants of Cancer Care."

Ellen Matloff on the Supreme Court Gene Patenting Decision

By Ellen T. Matloff, MS, CGC

June 25th 2013

Ellen T. Matloff, MS, CGC, from the Yale School of Medicine/Yale Cancer Center, describes the impact of the US Supreme Court decision to restrict the patenting of segments of DNA in isolation.

Bone-Targeted Therapies Evolve in Prostate Cancer

By Devera Pine

May 13th 2013

The treatment of bone metastases in prostate cancer has changed over the years, and several options are now either available or under development.

Dr. Herbst on Selecting Patients for Molecular Testing

By Roy S. Herbst, MD, PhD

April 30th 2013

Roy S. Herbst, MD, PhD, from the Yale Cancer Center, discusses determining the eligibility of patients with non-small cell lung cancer for molecular testing.

Should Sentinel Lymph Node Biopsy Be Postponed Until After Neoadjuvant Therapy?

By Jennifer Klem, PhD

April 24th 2013

With increasing use of neoadjuvant chemotherapy in early-stage breast cancer, controversy has erupted regarding the optimal timing of sentinel lymph node biopsy.

BATTLE-2: Next-Generation of Biomarker-Driven Trials

By Susan R. Peck, PhD

February 8th 2013

While the number of known mutations and matching targeted agents is relatively limited at present, clinical trials are being designed to identify effective therapies for specific mutations more efficiently.

Dr. Gettinger on Lung Cancer Immunotherapies

By Scott Gettinger, MD

January 8th 2013

Scott Gettinger, MD, associate professor of medicine (medical oncology), Yale School of Medicine, explains the development of immunotherapies in lung cancer.

Robust Sipuleucel-T Immune Activity Is Detailed in Pooled Data Analysis

By Ben Leach

October 24th 2012

Patients who received sipuleucel-T developed immune parameters that correlated with improved overall survival suggesting that these parameters should be the focus of further studies on the treatment.

Dr. Herbst Explores Molecular Testing in Lung Cancer

By Roy S. Herbst, MD, PhD

August 15th 2012

Dr. Roy S. Herbst, from Yale Cancer Center, Explores Molecular Testing in Lung Cancer

Making a Mark in Lung Cancer: An Interview With Roy S. Herbst, MD, PhD

By Beth Fand Incollingo

October 4th 2011

Roy S. Herbst, MD, PhD, is a physician and translational researcher, whose work in developing novel, personalized therapies for lung cancer has helped drive significant changes in the way the disease is treated.